These results demonstrate that FSTL1 exerts direct cardioprotective action by promoting angiogenesis, increasing FSTL1 protein content and activating TGFβ-Smad2/3 signaling in the post-MI heart, all of which mitigate heart dysfunction. The gene discussed is TGFB1; the disease is myocardial infarction.